Abstract
During the 2018–2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus–based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)–specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.)
Cite
CITATION STYLE
Mbala-Kingebeni, P., Pratt, C., Mutafali-Ruffin, M., Pauthner, M. G., Bile, F., Nkuba-Ndaye, A., … Muyembe Tamfum, J.-J. (2021). Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease. New England Journal of Medicine, 384(13), 1240–1247. https://doi.org/10.1056/nejmoa2024670
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.